Invivyd Completes Enrollment in Phase 3 LIBERTY Trial for COVID-19 Antibody vs. mRNA Vaccine

Event summary

  • Invivyd completed enrollment in its Phase 3 LIBERTY trial comparing VYD2311 antibody to mRNA COVID-19 vaccine.
  • The trial includes 210 participants and evaluates safety, tolerability, and immune response.
  • Topline data expected in Q3 2026, potentially alongside DECLARATION trial results.
  • VYD2311 aims to offer an alternative to vaccines with potentially fewer side effects.
  • LIBERTY is part of Invivyd’s broader REVOLUTION clinical program.

The big picture

Invivyd’s LIBERTY trial completion marks a critical step in evaluating VYD2311 as a potential alternative to mRNA COVID-19 vaccines. The trial’s direct comparison of antibody prophylaxis and vaccination could reshape preventive strategies, particularly if VYD2311 shows fewer side effects. Success in this trial would strengthen Invivyd’s position in the biopharmaceutical sector, especially as COVID-19 remains a global health concern.

What we're watching

Clinical Efficacy
Whether VYD2311 demonstrates superior tolerability and immune response compared to mRNA vaccines.
Regulatory Pathway
The pace at which Invivyd advances VYD2311 through FDA approval processes.
Market Positioning
How Invivyd positions VYD2311 as a preferred alternative to existing COVID-19 prevention methods.